Uploaded December 2024 | Updated September 2026, 1 week ago
At the 2024 RNDS, Dr. Benjamin Greenberg of the University of Texas Southwestern gave an update on the current state of stem cell therapies for rare neuroimmunologic disorders, focusing particularly on transverse myelitis. Recent studies, including the Mayo Clinic's research on stem cells for spinal cord injury, were reviewed, highlighting the progress and challenges faced in the field [00:01:05]. Dr. Greenberg discussed the risks and drawbacks of unregulated stem cell clinics and emphasized the importance of rigorous clinical trials and FDA approvals [00:02:42]. The presentation concluded with an update on the current FDA-approved Phase I trial using Q cells, detailing the procedures, safety measures, and future outlook [00:09:01]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Greenberg.pdf
00:00 Introduction to Stem Cell Therapies
00:37 Excitement and Challenges in Stem Cell Research
01:05 Case Study: Mayo Clinic's Stem Cell Research
02:42 The Reality of Stem Cell Clinics
03:52 History and Critique of Stem Cell Clinics
06:32 Scientific Approach to Stem Cell Therapy
06:53 Types of Stem Cells and Their Challenges
09:01 Preclinical Development and Testing
09:49 FDA Approval Process and Challenges
11:40 Clinical Trials and Patient Participation
14:12 Surgical Techniques and Innovations
19:00 Current Status and Future Directions
23:01 Acknowledgements and Personal Notes
At the 2024 RNDS, Dr. Benjamin Greenberg of the University of Texas Southwestern gave an update on the current state of stem cell therapies for rare neuroimmunologic disorders, focusing particularly on transverse myelitis. Recent studies, including the Mayo Clinic's research on stem cells for spinal cord injury, were reviewed, highlighting the progress and challenges faced in the field [00:01:05]. Dr. Greenberg discussed the risks and drawbacks of unregulated stem cell clinics and emphasized the importance of rigorous clinical trials and FDA approvals [00:02:42]. The presentation concluded with an update on the current FDA-approved Phase I trial using Q cells, detailing the procedures, safety measures, and future outlook [00:09:01]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Greenberg.pdf
00:00 Introduction to Stem Cell Therapies
00:37 Excitement and Challenges in Stem Cell Research
01:05 Case Study: Mayo Clinic's Stem Cell Research
02:42 The Reality of Stem Cell Clinics
03:52 History and Critique of Stem Cell Clinics
06:32 Scientific Approach to Stem Cell Therapy
06:53 Types of Stem Cells and Their Challenges
09:01 Preclinical Development and Testing
09:49 FDA Approval Process and Challenges
11:40 Clinical Trials and Patient Participation
14:12 Surgical Techniques and Innovations
19:00 Current Status and Future Directions
23:01 Acknowledgements and Personal Notes
